FDA-Approved Vaccines for Melanoma
Only one vaccine, Talimogene laherparepvec (T-VEC), has received FDA approval for melanoma treatment—it is an oncolytic viral therapy approved for unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients after initial surgery. 1
What T-VEC Is and How It's Used
T-VEC is technically an oncolytic herpes simplex virus-based immunotherapy rather than a traditional preventive or therapeutic vaccine. It works by:
- Selectively replicating in tumor cells and causing their lysis
- Expressing GM-CSF to stimulate systemic anti-tumor immunity
- Being administered as direct intralesional injection into accessible melanoma lesions
This is the ONLY vaccine-type therapy currently FDA-approved specifically for melanoma. 1
What About Other Melanoma Vaccines?
Despite decades of research and over 400 clinical trials investigating therapeutic melanoma vaccines 2, no traditional cancer vaccines have achieved FDA approval for melanoma 1, 3. The landscape includes:
Vaccine Platforms Tested But Not FDA-Approved:
- Peptide/recombinant protein vaccines (186 trials)
- Cellular vaccines including dendritic cell vaccines (151 trials)
- Nucleic acid vaccines including mRNA platforms (58 trials)
- Whole-cell vaccines like Canvaxin (showed promise in Phase II but never FDA-approved) 4
The Translation Problem:
A severe "translational funnel effect" exists 2:
- 63.6% of trials remain in Phase I/I-II
- Only 6.1% reach Phase III
- 22.9% termination rate
- Most trials focus on safety/immunogenicity rather than survival endpoints
Current FDA-Approved Melanoma Treatments (Not Vaccines)
The evidence clearly shows FDA-approved systemic therapies for melanoma include 5, 6:
For Adjuvant Therapy (Resected Disease):
- Immune checkpoint inhibitors: Nivolumab, pembrolizumab, ipilimumab
- BRAF/MEK inhibitors: Dabrafenib plus trametinib (for BRAF V600E/K mutations)
For Unresectable/Metastatic Disease:
- Immune checkpoint inhibitors: Nivolumab, pembrolizumab, ipilimumab, nivolumab plus relatlimab
- BRAF/MEK combinations: Dabrafenib plus trametinib, encorafenib plus binimetinib, vemurafenib plus cobimetinib
Emerging Vaccine Approaches
Neoadjuvant pembrolizumab (an immune checkpoint inhibitor, not a vaccine) is now recommended for resectable stage IIIB-IV melanoma 6, representing the closest current approach to "priming" the immune system before definitive surgery.
Recent promising developments include:
- mRNA-4157 (personalized neoantigen vaccine) plus pembrolizumab reduced recurrence/death risk by 49% in resected melanoma 2
- RP1 (oncolytic virus) plus nivolumab achieved 58.3% ORR in ICI-resistant patients 2
However, none of these are FDA-approved yet—they remain investigational.
Clinical Bottom Line
If a patient asks about melanoma vaccines:
- T-VEC is the only FDA-approved option, limited to intralesional injection for accessible unresectable lesions
- Standard FDA-approved treatments are immune checkpoint inhibitors and targeted therapies, not vaccines
- Clinical trials of personalized mRNA vaccines and other platforms are ongoing but not yet approved
- Combination approaches (vaccines plus checkpoint inhibitors) show the most promise in trials 1, 2
The distinction matters: while T-VEC uses vaccine-like immune mechanisms, the proven survival benefits in melanoma come from checkpoint inhibitors and targeted therapies, not traditional therapeutic vaccines.